Brexit Update – What will happen next?
25 March 2019 – 2pm (GMT)
25 Mar 2019
With the turmoil and uncertainty surrounding Britain’s exit from the EU the new arrangements for all aspects of the regulation of Pharmaceuticals, Medical Devices and IVDs between the UK and EU 27 pose major challenges.
This webinar will provide the latest information on Brexit and how it will affect the life sciences sector. Dr David Jefferys will discuss where we are now, and what the key issues will be going forward, discussing the changes that will be required and what solutions and plans may need to be into place.
There will be a discussion session following his presentation, to enable you to ask your individual questions on the outstanding issues.
Dr David Jefferys is currently Senior Vice President with Eisai responsible for Global Regulatory, Government Relations, Public Affairs and Patient Safety (EMEA, Russia and Australasia). After qualifying in medicine he worked in clinical and academic medicine, before spending 20 years as a senior regulator for both medicines and medical devices. He was executive director of the UK Medicines Control Agency, CEO and Director of the MDA, joint CEO of MHRA. He was involved in the establishment of the European Medicines Agency, CPMP/CHMP member and MRFG and PER scheme chairman. For the last ten years he has worked in industry and chairs several key committees for ABPI, Efpia and IFPMA. He has lectured and published extensively in drug and device regulation and on benefit risk evaluation.